Massive Bio

Empowering cancer patients globally through our AI-based, clinical trial matching platform, always 100% free. Providing options & hope.

[Massive Bio @MassiveBio]

Massive Bio has been named an OpenAI Select Partner within the OpenAI Partner Network 🎉

Pairing GPT‑5.6 and ChatGPT Work with oncology-specific expertise to move AI in clinical research from pilots to production, with human oversight built in.

Read the press release: https://t.co/tymzgZVNQJ

#OpenAI #Oncology #ClinicalTrials #AIinHealthcare

[Massive Bio @MassiveBio]

Massive Bio has been named to @TIME's World's Top HealthTech Companies 2026 in AI & Data Analytics, produced with @StatistaCharts. Recognized alongside @DatavantHQ, @healthverity, @IQVIA_global, @ConcertAI, @TempusAI, @KomodoHealth, @SOPHiAGENETICS , and @SiemensHealth.

https://t.co/RhmZoVkXFt

#TIMEHealthTech2026 #OncologyAI #RealWorldData #PrecisionMedicine

[Massive Bio @MassiveBio]

Massive Bio is expanding into South Korea, appointing Intralink to build relationships with hospitals, labs and oncologists across the country's oncology sector, strengthening our real-world data network for pharma partners across Asia.

Read more: https://t.co/DZNjQQS1n0

#Oncology #ClinicalTrials #PrecisionMedicine #SouthKorea #CancerCare

[Massive Bio @MassiveBio]

Our Co-Founder and Chief Medical AI Officer, Arturo LoAIza-Bonilla MD (@DrArturoAI), joined the Riyadh Global Medical Biotechnology Summit (@rgmbs) to share how agentic AI is reshaping the path from diagnosis to treatment, representing the U.S. and Massive Bio on the global stage.

The core idea: a test result only matters if it leads somewhere. Too often, biomarker data sits disconnected from the next step, whether that's a clinical trial, a specialist referral, or a treatment change. Multi-agentic AI closes that gap, coordinating testing, trial matching, and navigation while keeping physicians firmly in control of the decisions that matter.

There's a bigger system taking shape here too: when patients consent to share their journeys, that data doesn't just help them, it feeds back into building smarter models and better therapies for the patients who come next. This is the loop we're building at Massive Bio: precision care informing research, research informing drug development, and each patient's outcome making the next one's care better.

Thank you to sponsors including @AstraZeneca, @Novartis , @thermofisher, @Roche and more for supporting this conversation on the global stage.

#PrecisionOncology #AgenticAI #RGMBS #Healthtech #AI

[Massive Bio @MassiveBio]

Massive Bio took the stage at GITEX AI Türkiye 2026 (@GitexTurkiye), held in strategic partnership with the Ministry of Industry and Technology.

Our Marketing Director Mert Türkkan and our Assistant Director, Product Management, Serkan Yerdan joined the @turcorn100 Lounge, with Serkan on stage on AI-driven trial matching and our growing collaborations with pharma partners.

Trial matching starts with the same groundwork as those collaborations: structuring unstandardized clinical inputs before any model can act on them.

#GITEXAiTurkiye #Turcorn100

[Massive Bio @MassiveBio]

Massive Bio and @precisca_ announce a strategic partnership to expand cancer patient access to clinical trials across the U.S., pairing AI driven trial matching with a national oncology provider network.

Read more: https://t.co/8wXfLk8p0C.

#PrecisionOncology #ClinicalTrials #Oncology

[Massive Bio @MassiveBio]

Massive Bio was proud to sponsor the FLASCO (@FLASCO_ORG) 2026 Clinical Oncology Series: Malignant Hematology in Tampa alongside @AstraZeneca, Geron, @LillyOncMed, @pfizer Oncology, and @TakedaOncology.

Representing Massive Bio on site were our Co-Founder, CTO & COO Çağatay M. Çulcuoğlu and our SVP, U.S. Provider Engagement and Partnerships, Toygun Onaran, joined by Dr. Henry Idrobo Quintero, Vice President of GELL, our partner organization advancing lymphoma and hematologic malignancy research across Latin America.

Thank you to everyone who stopped by to connect and learn more about how Massive Bio helps expand access to clinical trials for patients with hematologic malignancies.

@FLASCO_ORG @Grupo_GELL

#ClinicalTrials #Hematology #Oncology

[Massive Bio @MassiveBio]

🔴 LIVE TODAY · 12:00 EDT / 18:00 CEST

Our Co-Founder & Chief Medical AI Officer Arturo Loaiza-Bonilla (@DrArturoAI) is moderating "AI in Community Oncology: From Clinical Decision Support to Workflow Transformation" at the Community Oncology Global Congress 2026.

Most people with cancer are treated in the community, not academic centers. If AI doesn't work there, it doesn't work.

Four talks, then a moderated discussion with the people building, vetting, and using these tools in real clinics, plus a panel of practicing oncologists.

What's ready for routine use today? What evidence should a practice demand before trusting a tool? Where does AI take work off the clinician's plate instead of adding to it?

One hour. Practical answers. Global perspectives.

🔗 https://t.co/xg0yCCFbFo

#AIinOncology #CommunityOncology #DigitalHealth #CancerCare #ClinicalAI @oncodaily

[Massive Bio @MassiveBio]

Massive Bio is heading to GITEX AI 2026 (Sept 9–10), joining the @turcorn100 program on the Turcorn Lounge stage alongside the country's top AI and tech companies.

On-site: Çağatay Çulcuoğlu (Co-Founder, CTO & COO), Mert Türkkan (Marketing Director), and Serkan Yerdan (Assistant Director, Product Management).

Excited to showcase how AI is transforming precision oncology and connect with the broader AI and healthcare innovation community at this year's event.

Learn more: https://t.co/bxgiJiQeeg

@GITEX_GLOBAL @GitexTurkiye

[Massive Bio @MassiveBio]

At Massive Bio, we believe our impact extends beyond the work we do in oncology and clinical trial access. It is also shaped by the values our colleagues carry into their communities.

We are proud to share that our colleague, Toygun Onaran, SVP of U.S. Provider Engagement and Partnerships, has been recognized by the American Lung Association (@LungAssociation) for his distinguished service, loyalty, and exemplary contributions as a member of its South Florida Leadership Board for the 2025-2026 term.

Recognitions like this reflect the kind of people who make up the Massive Bio team: individuals committed not only to advancing patient care, but to strengthening public health in the communities we serve. We are grateful to have colleagues like Toygun representing Massive Bio's values so well, both within our organization and beyond it.

#Leadership #CommunityHealth #PublicHealth #Oncology #HealthcareLeadership

[Massive Bio @MassiveBio]

Massive Bio is proud to sponsor the FLASCO (@FLASCO_ORG) 2026 Clinical Oncology Series: Malignant Hematology, taking place August 29 in Tampa at the Renaissance Tampa International Plaza Hotel.

Representing Massive Bio on-site will be Our Co-Founder, CTO & COO Çağatay M. Çulcuoğlu and our SVP, U.S. Provider Engagement and Partnerships, Toygun Onaran, joined by Dr. Henry Idrobo Quintero, Vice President of GELL, our partner organization advancing lymphoma and hematologic malignancy research across Latin America.

Stop by our booth to connect with the team and learn how Massive Bio is helping match patients with hematologic malignancies to the right clinical trials, faster.

We look forward to engaging with the oncology and hematology community in Tampa.

#Oncology #ClinicalTrials #CancerResearch #PrecisionMedicine #HealthcareInnovation #DigitalHealth #HealthTech #MedicalConferences

[Massive Bio @MassiveBio]

We ask for your medical records for one reason: it's the only way to find trials that actually match your diagnosis.

Your information is protected at every step, never sold, never shared beyond your care.

Questions? We're here: https://t.co/fMPbrNQQut

[Massive Bio @MassiveBio]

AI is starting to close a long-standing gap in cancer care: connecting patients to the right clinical trial, faster and at scale.

Our Co-Founder & CEO Selin Kurnaz joined @SaulMarquez on the Outcomes Rocket podcast to talk about how Massive Bio is building a scalable, end-to-end journey for cancer patients — regardless of where they live or what they can afford.

🎧https://t.co/xE6qiNX349

#ClinicalTrials #PrecisionOncology #AI

[Massive Bio @MassiveBio]

Reaching out about a clinical trial can feel like stepping into the unknown. It doesn't have to.

Here's exactly what happens after you contact us, step by step:

1️⃣ You tell us a little about your diagnosis and give your consent to move forward
2️⃣ We request your medical records and review your case for trials that actually fit
3️⃣ We match you with real options and stay with you through the next steps

No confusing forms. No jargon. No guesswork.

Ready to see what's out there for you? Link in bio to get started.

#ClinicalTrials #CancerSupport #PrecisionOncology #PatientAdvocacy #MassiveBio #CancerJourney #KnowYourOptions

[Massive Bio @MassiveBio]

🎙️ New episode of Massively Insightful!

Our Co-Founder and CEO Selin Kurnaz talks with Christopher P. Boone, PhD (Oracle, GVP Research & Services for Life Sciences) about AI in drug discovery, real-world evidence, AI governance, and digital twins in healthcare.

🎧 Listen now:
Spotify: https://t.co/BcGD5FO1uu
Amazon Music: https://t.co/661u8jrSE0
Apple Podcasts: https://t.co/JfYYvXmxeH

Learn more: https://t.co/CWw0FpMzKj

#MassivelyInsightful #HealthcareAI #PrecisionOncology #ClinicalTrials #DigitalHealth

[OncoDaily @oncodaily]

Massive Bio - Building the Next Generation of AI-Driven Cancer Care with Rivvi AI

@MassiveBio @DrArturoAI

https://t.co/dFIiGU58il

[Massive Bio @MassiveBio]

Massive Bio just made its first-ever strategic investment in another AI company: Rivvi AI, an agentic AI infrastructure company for healthcare and life sciences.

Together, we're connecting validated oncology intelligence with governed AI-powered patient engagement, moving patients from identification to informed action.

Announced today at #Ai4 2026.

Read the full press release here: https://t.co/Y2W3Oai4oh

#Oncology #AI #HealthTech #ClinicalTrials #PrecisionMedicine #CancerCare #DigitalHealth #Ai4

[Massive Bio @MassiveBio]

We're excited to share that Massive Bio has been named an @OpenAI Select Partner.

As part of the OpenAI Partner Network, we look forward to continuing our work with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively.

We're proud to be part of this next chapter. Learn more: https://t.co/6JEgdTNLK7

#OpenAISelectPartner #OpenAIPartnerNetwork #EnterpriseAI

[Massive Bio @MassiveBio]

Massive Bio and QC Healthcare are teaming up to close critical gaps in the cancer journey, pairing AI-powered trial matching with nationwide telehealth so patients get coordinated care without ever leaving the trials that could save their lives. Trial matching stays free to patients.

https://t.co/cU9sexTgtz

#Oncology #ClinicalTrials #AI

[Massive Bio @MassiveBio]

Massive Bio and GELL (@Grupo_GELL) (Latin American Study Group on Lymphoproliferative Disorders) announce a strategic partnership to advance research, physician education, and AI adoption in oncology across Latin America and the U.S.

Read more: https://t.co/T7xANGFcv7